Correlation Between Inozyme Pharma and Scynexis
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Scynexis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Scynexis into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Scynexis, you can compare the effects of market volatilities on Inozyme Pharma and Scynexis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Scynexis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Scynexis.
Diversification Opportunities for Inozyme Pharma and Scynexis
0.83 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Inozyme and Scynexis is 0.83. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Scynexis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scynexis and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Scynexis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scynexis has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Scynexis go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Scynexis
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Scynexis. In addition to that, Inozyme Pharma is 1.72 times more volatile than Scynexis. It trades about -0.73 of its total potential returns per unit of risk. Scynexis is currently generating about -0.29 per unit of volatility. If you would invest 142.00 in Scynexis on August 27, 2024 and sell it today you would lose (18.00) from holding Scynexis or give up 12.68% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Scynexis
Performance |
| Timeline |
| Inozyme Pharma |
| Scynexis |
Inozyme Pharma and Scynexis Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Scynexis
The main advantage of trading using opposite Inozyme Pharma and Scynexis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Scynexis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scynexis will offset losses from the drop in Scynexis' long position.| Inozyme Pharma vs. Eliem Therapeutics | Inozyme Pharma vs. HCW Biologics | Inozyme Pharma vs. Scpharmaceuticals | Inozyme Pharma vs. Milestone Pharmaceuticals |
| Scynexis vs. Biofrontera | Scynexis vs. Shuttle Pharmaceuticals | Scynexis vs. Akanda Corp | Scynexis vs. China Pharma Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |